Investment Thesis
Alzamend Neuro is a pre-revenue pharmaceutical company in a critical financial deterioration phase, with revenue collapsing 87.7% YoY to just $1.7K while operating losses remain severe at $5.9M. The company is burning cash rapidly at $5.3M annually with minimal liquidity cushion, making near-term solvency a material concern despite holding $2.7M in cash reserves.
Strengths
- Maintains positive stockholders equity of $2.2M providing minimal balance sheet foundation
- Cash on hand of $2.7M covers approximately 5 months of current burn rate
- Low debt burden (0.00x debt-to-equity) eliminates refinancing risk
Risks
- Revenue near zero at $1.7K indicates complete absence of commercial traction or product sales
- Current ratio of 0.97x indicates immediate liquidity stress with liabilities nearly exceeding current assets
- Operating cash burn of $5.3M annually will exhaust cash reserves within months without capital injection, creating existential solvency risk
- Extreme negative margins across all profitability metrics indicate unsustainable operating model
- Pre-revenue stage with no clear path to profitability or positive cash flow
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Revenue generation and clinical trial progression
- Upcoming capital raises and dilution risk
- Operating expense reduction initiatives
Financial Metrics
Revenue
1.7K
Net Income
-5.9M
EPS (Diluted)
$-1.89
Free Cash Flow
-5.3M
Total Assets
4.0M
Cash
2.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-345,601.6%
Net Margin
-345,980.8%
ROE
-270.2%
ROA
-146.0%
FCF Margin
-308,940.2%
Balance Sheet & Liquidity
Current Ratio
0.97x
Quick Ratio
0.97x
Debt/Equity
0.00x
Debt/Assets
46.0%
Interest Coverage
-911.42x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T18:07:15.908591 |
Data as of: 2026-01-31 |
Powered by Claude AI